Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer

Gene Therapy volume 24, pages 392–398 (2017)Cite this article

Subjects

Abstract

This study aimed to investigate the correlation between INSR gene polymorphisms on platinum-based chemotherapy sensitivity and prognosis in epithelial ovarian cancer (EOC). A total of 339 EOC patients receiving postoperative chemotherapy were recruited for the study. Tag single-nucleotide polymorphism of INSR gene was screened from HapMap combined with available literature. Frequency distribution of genotypes and alleles in INSR gene was sequenced by ABI3100-Avant. Compared with CC+GC genotype, INSR rs2252673 GG genotype and rs3745546 CC genotype showed less platinum-based chemotherapy sensitivity in EOC patients (odds ratio (OR)=0.269, 95% confidence interval (CI)=0.159~0.456; OR=0.445, 95% CI=0.214~0.926, respectively), as well as serous EOC patients (OR=0.083, 95% CI=0.024~0.278; OR=0.235, 95%CI=0.053~1.041, respectively). The clinical characteristics including age, clinical stage, histological grade and residual lesion size were significantly related with chemosensitivity to platinum drugs and mortality in EOC patients. According to Kaplan–Meier curve, compared with CC+GC genotype, rs2252673 GG genotype showed significantly decreased survival rate in EOC patients (P<0.05). Cox regression model indicated that rs2252673, age and clinical stage were independent risk factors for the prognosis in EOC (all P<0.05). These findings indicate that INSR rs2252673 and rs3745546 polymorphisms were associated with sensitivity to platinum-based chemotherapy in EOC patients and rs2252673 polymorphism may be an independent risk factor for EOC prognosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Sakalar C, Mazumder S, Johnson JM, Altuntas CZ, Jaini R, Aguilar R et al. Regulation of murine ovarian epithelial carcinoma by vaccination against the cytoplasmic domain of anti-Mullerian hormone receptor II. J Immunol Res 2015; 2015: 630287.

    Article  Google Scholar 

  2. Sestito R, Cianfrocca R, Rosano L, Tocci P, Semprucci E, Di Castro V et al. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget 2015; 7: 4009–4023.

    PubMed Central  Google Scholar 

  3. Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.

    Article  Google Scholar 

  4. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203: e221–e226.

    Article  Google Scholar 

  5. Ludwig AH, Murawska M, Panek G, Timorek A, Kupryjanczyk J . Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer 2009; 16: 1005–1016.

    Article  CAS  Google Scholar 

  6. Tecza K, Pamula-Pilat J, Kolosza Z, Radlak N, Grzybowska E . Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy. J Exp Clin Cancer Res 2015; 34: 2.

    Article  Google Scholar 

  7. Cook LS, Leung AC, Swenerton K, Gallagher RP, Magliocco A, Steed H et al. Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study. Gynecol Oncol 2016; 140: 277–284.

    Article  CAS  Google Scholar 

  8. Rauh-Hain JA, Foley OW, Winograd D, Andrade C, Clark RM, Vargas RJ et al. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol 2015; 212: e601–e608.

    Article  Google Scholar 

  9. Li K, Li W . Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population. Mol Cell Biochem 2013; 372: 27–33.

    Article  CAS  Google Scholar 

  10. Mukherjee S, Shaikh N, Khavale S, Shinde G, Meherji P, Shah N et al. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur J Endocrinol 2009; 160: 855–862.

    Article  CAS  Google Scholar 

  11. Lee EJ, Oh B, Lee JY, Kimm K, Lee SH, Baek KH . A novel single nucleotide polymorphism of INSR gene for polycystic ovary syndrome. Fertil Steril 2008; 89: 1213–1220.

    Article  CAS  Google Scholar 

  12. Goodarzi MO, Louwers YV, Taylor KD, Jones MR, Cui J, Kwon S et al. Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertil Steril 2011; 95: 1736–1741; e1–11.

    Article  CAS  Google Scholar 

  13. Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S . Genetic syndromes of severe insulin resistance. Endocr Rev 2011; 32: 498–514.

    Article  CAS  Google Scholar 

  14. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012; 2012: 789174.

    Article  Google Scholar 

  15. Feng C, Lv PP, Yu TT, Jin M, Shen JM, Wang X et al. The association between polymorphism of INSR and polycystic ovary syndrome: a meta-analysis. Int J Mol Sci 2015; 16: 2403–2425.

    Article  CAS  Google Scholar 

  16. Ofer P, Heidegger I, Eder IE, Schopf B, Neuwirt H, Geley S et al. Both IGF1R and INSR knockdown exert antitumorigenic effects in prostate cancer in vitro and in vivo. Mol Endocrinol 2015; 29: 1694–1707.

    Article  CAS  Google Scholar 

  17. Khrunin AV, Moisseev A, Gorbunova V, Limborska S . Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010; 10: 54–61.

    Article  CAS  Google Scholar 

  18. Scully RE . World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr 1975; 42: 5–7.

    CAS  PubMed  Google Scholar 

  19. De Angelis V . [Activity, objective response, and WHO and RECIST (Response Evaluation Criteria In Solid Tumor) evaluation criteria]. Suppl Tumor 2004; 3: S7–S9.

    Google Scholar 

  20. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010; 116: 4043–4053.

    Article  CAS  Google Scholar 

  21. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011; 117: 1661–1669.

    Article  CAS  Google Scholar 

  22. Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P et al. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol 2012; 124: 142–147.

    Article  CAS  Google Scholar 

  23. Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Onen HI et al. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet 2009; 26: 205–216.

    Article  Google Scholar 

  24. Lee EJ, Yoo KJ, Kim SJ, Lee SH, Cha KY, Baek KH . Single nucleotide polymorphism in exon 17 of the insulin receptor gene is not associated with polycystic ovary syndrome in a Korean population. Fertil Steril 2006; 86: 380–384.

    Article  CAS  Google Scholar 

  25. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43: 55–59.

    Article  Google Scholar 

  26. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 2012; 44: 1020–1025.

    Article  CAS  Google Scholar 

  27. Du J, Wang J, Sun X, Xu X, Zhang F, Wang B et al. Family-based analysis of INSR polymorphisms in Chinese PCOS. Reprod Biomed Online 2014; 29: 239–244.

    Article  CAS  Google Scholar 

  28. Du J, Wang Z, Zhang J, Jia L, Zhang F, Shi Y et al. [Association between single nucleotide polymorphism of rs2252673 of INSR gene and polycystic ovarian syndrome]. Zhonghua Fu Chan Ke Za Zhi 2014; 49: 919–924.

    CAS  PubMed  Google Scholar 

  29. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009; 113: 264–269.

    Article  CAS  Google Scholar 

  30. Steffensen KD, Waldstrom M, Jakobsen A . The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19: 820–825.

    Article  Google Scholar 

  31. Seino S, Seino M, Nishi S, Bell GI . Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci USA 1989; 86: 114–118.

    Article  CAS  Google Scholar 

  32. Jochumsen KM, Tan Q, Hogdall EV, Hogdall C, Kjaer SK, Blaakaer J et al. Gene expression profiles as prognostic markers in women with ovarian cancer. Int J Gynecol Cancer 2009; 19: 1205–1213.

    Article  Google Scholar 

  33. Saini V . Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes 2010; 1: 68–75.

    Article  Google Scholar 

  34. Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S . [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy]. Zhonghua Fu Chan Ke Za Zhi 2013; 48: 847–852.

    CAS  PubMed  Google Scholar 

  35. Soonthornthum T, Suraseraneewong V, Kengsakol K, Wijaithum K, Kasemsan P, Prommatt S . Thrombocytosis in advanced epithelial ovarian cancer. J Med Assoc Thai 2007; 90: 1495–1500.

    PubMed  Google Scholar 

  36. Thavaramara T, Phaloprakarn C, Tangjitgamol S, Manusirivithaya S . Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thai 2011; 94: 871–877.

    PubMed  Google Scholar 

  37. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T . Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012; 23: 265–273.

    Article  Google Scholar 

  38. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009; 58: 15–23.

    Article  CAS  Google Scholar 

  39. Asher V, Lee J, Innamaa A, Bali A . Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 2011; 13: 499–503.

    Article  Google Scholar 

Download references

Acknowledgements

We give our sincere appreciation to the reviewers for their helpful comments on this study. This work was supported by grants from Henan Provincial Science and Technique Program (162102310014) and Henan Provincial Medical Science and Technique Program (201602218).

Author information

Authors and Affiliations

  1. Department of Oncology, The People’s Hospital of Zhengzhou University and Henan Provincial People’s Hospital, Zhengzhou, China

    J-L Hu, C-J Wang, Y-Y Wen & S-D Cang

  2. Department of Medical Imaging Technology, Henan University of Chinese Medicine, Zhengzhou, China

    X-L Hu

  3. Department of Radiotherapy, The People’s Hospital of Zhengzhou University and Henan Provincial People’s Hospital, Zhengzhou, China

    Q Han

  4. Department of Clinical Laboratory, The People’s Hospital of Zhengzhou University and Henan Provincial People’s Hospital, Zhengzhou, China

    A-Y Guo

Authors
  1. J-L Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X-L Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Q Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A-Y Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C-J Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y-Y Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S-D Cang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S-D Cang.

Ethics declarations

Competing interests

The authors have declared that no competing interests exist

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, JL., Hu, XL., Han, Q. et al. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer. Gene Ther 24, 392–398 (2017). https://doi.org/10.1038/gt.2017.26

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2017.26

This article is cited by

Search

Advanced search

Quick links